Reclast News
Most Popular Reclast Story
Novartis' Reclast gets FDA blessing
Score one for Novartis. Its once-yearly treatment for post-menopausal osteoporosis, Reclast, now has the FDA's blessing. Already approved in the U.S. and E.U. for treatment of Paget's bone disease, Read more...
Latest Headlines
- September 12, 2011
- September 6, 2011
- March 10, 2011
- October 14, 2010
- June 1, 2009
- November 13, 2008
- June 5, 2008
- January 8, 2008
- October 5, 2007
- September 18, 2007
- August 20, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
